188 related articles for article (PubMed ID: 10078713)
1. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
[TBL] [Abstract][Full Text] [Related]
2. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959
[TBL] [Abstract][Full Text] [Related]
3. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
Imbimbo BP; Troetel WM; Martelli P; Lucchelli F
Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357
[TBL] [Abstract][Full Text] [Related]
4. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
Imbimbo BP; Verdelli G; Martelli P; Marchesini D
Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Canal N; Imbimbo BP
Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
7. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
8. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
van Dyck CH; Newhouse P; Falk WE; Mattes JA
Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
[TBL] [Abstract][Full Text] [Related]
9. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
11. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
13. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
14. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
Braida D; Sala M
CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
[TBL] [Abstract][Full Text] [Related]
15. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
Sramek JJ; Block GA; Reines SA; Sawin SF; Barchowsky A; Cutler NR
Life Sci; 1995; 56(5):319-26. PubMed ID: 7837931
[TBL] [Abstract][Full Text] [Related]
16. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
17. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
[TBL] [Abstract][Full Text] [Related]
18. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
19. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.
Tariot PN; Solomon PR; Morris JC; Kershaw P; Lilienfeld S; Ding C
Neurology; 2000 Jun; 54(12):2269-76. PubMed ID: 10881251
[TBL] [Abstract][Full Text] [Related]
20. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
